secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001171843-22-005357
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos reports Q2 net loss $19.9M ($0.47), cash $159.3M, advances HBV/siRNA programs
--------------------------------------------------------------------------------

- Net loss $19.9M ($0.47/share) vs $29.8M ($0.79) in Q2 2021.
- Cash & investments $159.3M at June 30, 2022 (down from $205.8M at Dec 31, 2021); funds ops into H1 2024.
- R&D expenses decreased to $16.5M from $24.6M YoY, reflecting STOPS/ASO wind-down.
- Completed enrollment in multiple CAM-2 and NASH Phase 1 cohorts; on track to file CTA for siRNA ALG-125755 in Q3 2022.
- COVID-19 3CL PI ALG-097558 shows only 3-fold EC50 shift against resistant mutant vs >50-fold for nirmatrelvir.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184322005357/0001171843-22-005357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184322005357/f8k_080322.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-005357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer